Enara Bio Company

Ervaxx is illuminating the immune interface to develop new cancer therapies.
Technology: Tumor-Specific Antigens
Industry: Tumor-Specific Antigens
Headquarters: London, England, United Kingdom
Founded Date: 2016-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 2
Total Funding: 17500000
Estimated Revenue: $1M to $10M
Last Funding Date: 2019-11-06
Last Funding Type: Series A

Visit Website
Register and Claim Ownership